newsfilter
← Latest News
PR Newswire·

Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

  • Karyopharm Therapeutics Inc. will host a conference call on Tuesday, June 2, 2026, at 2:00 p.m. ET.
  • The call will feature senior management & Dr. John Mascarenhas, principal investigator of the Phase 3 SENTRY trial.
  • Discussion topics include Phase 3 SENTRY trial results for selinexor plus ruxolitinib in myelofibrosis.
  • The presentation follows Dr. Mascarenhas' oral presentation at the 2026 ASCO Annual Meeting.
  • Participants may dial (800) 836-8184 (local) or (646) 357-8785 (international) 10 minutes prior to the start.
  • A live audio webcast & slides will be available on the Investor section of Karyopharm's website under "Events & Presentations".
  • An archived webcast will be available approximately two hours after the event.
  • Karyopharm is a commercial-stage company pioneering nuclear export inhibition with lead therapy XPOVIO® (selinexor).
  • XPOVIO is approved in the U.S. for relapsed/refractory multiple myeloma & in over 50 ex-U.S. countries as XPOVIO or NEXPOVIO®.
  • The Company is advancing selinexor in hematologic & solid tumor cancers, including myelofibrosis & TP53 wild-type endometrial cancer.
  • Karyopharm is evaluating XPO1 inhibition across myeloproliferative neoplasms & solid tumors using next-generation compounds like eltanexor.